ArchiMed
ArchiMed is an independent asset management company with offices in New York, Lyon, Singapore and Tokyo, founded in 2014, that acts as a strategic and financial partner in the healthcare industries, mainly in Europe and the United States.
ArchiMed has over 200 staff members, including investors and former healthcare professionals. The company has €8 billion of assets under management and has raised six funds around three strategies of growth buyout, lower mid cap (MED), mid cap (MED platform) and more recently small cap (MED rise). ArchiMed launched MED Platform I (a €1 billion fund) in 2018 and MED Platform II (€3.5 billion) in 2022. The funds aim to accelerate the growth of European and American companies selected for their potential for international development and consolidation.
At the end of 2024, MED Platform I had invested in seven platforms, including one that had been sold: Bomi Group (a leading European provider of specialist contract logistics for medical equipment manufacturers: investment made in 2019 and sold in 2022 for a return of 4.0x), Direct Healthcare Group (a leading European provider of specialist hospital equipment for the prevention and treatment of pressure ulcers, investment made in late 2019), NAMSA (a world-leading contract research provider to medical equipment manufacturers, investment made in 2020), Stragen (a pharmaceuticals company specialising in complex generic drugs in niche markets, investment made in 2021), Prollenium (producer of medical aesthetic products specialising in cutaneous injections of hyaluronic acid, investment made in 2021), Suanfarma (producer and distributor of pharmaceutical and nutraceutical products, investment made in 2021) and Carso (joint leader in the French testing services market, investment made in 2021). At the end of 2024, the seven platforms of MED Platform I had completed some forty add-on acquisitions.
MED Platform II had invested in five companies at the end of 2024 in the following sectors: Medtech (Natus in neurodiagnostics and Irrimax in surgical consumables), Life Science Tools & Biologic Services (PlasmidFactory in plasmid DNA), Healthcare IT (Instem) and Consumer Health (Jeysis in aesthetic medical devices).
At the end of 2024, the MED III (€650 million, 2021 vintage) and MED Rise (€400 million, 2024 vintage) funds were invested in six and two companies respectively.
- Investment date
- 2018
In 2024
In 2024, ArchiMed invested in five new platforms (Cellese via MED III, Irrimax and Jeysis via MED Platform II and SeqCenter and FIM Medical via MED Rise) and did not sell any shareholdings.
Peugeot Invest's investment
In 2018, Peugeot Invest committed to invest up to €80 million, with the potential to double its exposure to companies of its choosing, taking its maximum commitment to €160 million. In 2021, Peugeot Invest committed €15 million to MED III, €100 million to MED Platform II in 2022 and €10 million to MED Rise in 2024.
In 2021, Peugeot Invest committed to co-invest a further €42 million (including €10 million in Bomi, which has since been sold), across four of the fund’s platforms (Bomi, Carso, Prollenium and Suanfarma). In 2022, an additional commitment of €10 million was to Natus.
Key figures
- MED Platform II investments
- 2 new